Introduction
Human chronic myeloid leukemia (CML) is a malignant hematopoietic disease characterized by the Philadelphia chromosome (Ph) due to reciprocal rearrangement between the breakpoint-cluster region (bcr) gene on chromosomes 22 and the Abelson leukemia (c-abl) gene on chromosome 9 (Rowley, 1990; Sawyers, 1999) . Cellular Abl kinase is negatively regulated by its amino-terminal region binding to the carboxyl-terminal tyrosine kinase domain (Nagar et al., 2003) , whereas the fused p210
BcrÀAbl sequence disrupts the autoinhibitory structure of Abl, leading to a constitutive protein tyrosine kinase (PTK) activity (Deininger et al., 2000; Ren, 2005) . Compelling evidence has shown that tyrosine kinase of p210
BcrÀAbl is required to cause transformation with uncontrolled proliferation, antiapoptosis and decreased adhesion to the bone marrow (BM) stroma (Deininger et al., 2000; Salesse and Verfaillie, 2002; Wertheim et al., 2002) , resulting in CML-like disease (Daley et al., 1990; Pear et al., 1998) .
CML cells circulate in large numbers in the blood at virtually all stages of differentiation, an indicator of uncoupling cell differentiation from the ability to leave the BM (Pear et al., 1998) . p210
BcrÀAbl when expressed in distinct hematopoietic cell lines, Ba/F3, 32D and Mo7e, significantly impairs their response in the directional migration assay to stromal-derived factor-1a (SDF-1a) (Salgia et al., 1999) , which is a chemokine constitutively secreted by reticular marrow stromal cells. Similarly, human CD34 þ progenitor cells expressing p210 BcrÀAbl also show defects in SDF-1a responsiveness (Ramaraj et al., 2004) . As SDF-1a is the major chemotactic agent that signals through chemokine (CXC motif) receptor 4 (CXCR4), a seven transmembrane G-protein-coupled receptor, to induce directional migration, and to attract stem and progenitor cells to the BM space (Burger and Burkle, 2007) , the reduction of SDF-1a responsiveness in p210
BcrÀAbl -transformed cells reflects the homing and retention defects of immature myeloid cells in CML peripheral blood. However, the mechanism(s) responsible for p210
BcrÀAbl -mediated changes in chemotactic migration remain unknown.
Small GTPases of the Rho family, including Rho, Rac and Cdc42, have essential functions in cell migration by transducing signals for cytoskeleton remodeling (Raftopoulou and Hall, 2004; Vicente-Manzanares and Sanchez-Madrid, 2004) . In migrating cells, Cdc42 and Rac1 establish F-actin-rich finger-like membrane extrusions (filopodia) and surface protrusions (lamellipodia), respectively, in the anterior for protrusive activity, whereas RhoA-ROCK mediates cortical myosin formation to generate retraction force at the posterior of the cell, moving cells forward (Niggli, 2003; Van Haastert and Devreotes, 2004) . Chemotaxis is a process in which cells sense gradients of chemoattractants to move toward higher concentrations of chemoattractants. In neutrophils, chemoattractant-ligated receptors trigger the Gbg-p21 activated kinase (PAK) 1/PAK-interacting exchange factor-a/Cdc42 pathway, which is essential for the localized polymerization of F-actin and the extension of a leading edge in a gradient-orientated polarization (Li et al., 2003; Macara, 2004) . For SDF-1a-mediated T cell migration, both Rac1 and Cdc42 activation are required for the chemotactic response (Volinsky et al., 2006) . In accordance, the loss of interaction between Cdc42 and its downstream effector Wiskott-Aldrich syndrome protein contributes to abnormal SDF-1a chemotaxis in T-lymphocytes of Wiskott-Aldrich syndrome patients (Haddad et al., 2001) . Moreover, homing of hematopoietic progenitor cells to the BM is also impaired by pre-treatment with lethal toxin from Clostridium sordellii, which inactivates Rho family GTPases, Cdc42 and Rac1, in mice (Genth et al., 1996) , whereas RhoA inactivation by Rho inhibitor, C2I-C3, does not alter the homing of hematopoietic progenitor cells in mice (Gottig et al., 2006) . Herein, we raised the question whether p210
BcrÀAbl impairs SDF-1a-mediated chemotaxis through Cdc42 and/or Rac1 pathway.
The molecular link between p210 BcrÀAbl and Rho GTPases has been shown in a number of reports. For example, p210
BcrÀAbl activates RhoA through its Dblhomology domain in the Bcr region, and its PTK located in the Abl region phosphorylates Vav1 for Rac1 activation (Daubon et al., 2008) . Vav1, known as a proto-oncogene, is predominantly expressed in hematopoietic cells (Matsuguchi et al., 1995; Hornstein et al., 2004) , and tyrosine phosphorylation of Vav1 by p210
BcrÀAbl in its acidic domain relieves its autoinhibition by exposing the Dbl-homology domain for interaction with GDP-Rac1, thereby catalyzing GTP exchange (Aghazadeh et al., 2000; Miletic et al., 2003) . Despite the functional implication of p210
BcrÀAbl in regulation of Rho GTPases, we know little about how p210 BcrÀAbl influences chemotactic migration. In this study, we present evidence that constitutive activation of Cdc42 by p210
BcrÀAbl signal is involved in the loss of SDF-1a-induced directional migration in CML cells.
Results

p210
BcrÀAbl expression alters SDF-1a-induced Cdc42 and Rac1 activation We first compared Cdc42/Rac1 activation after SDF-1a stimulation in murine myeloid progenitor 32D and p210
BcrÀAbl -transformed 32D (32Dp210) cells. As expected, 32D cells showed a marked increase in GTP bound form of Cdc42 and Rac1 on treatment with SDF1a for 5 min (Figures 1a and b) . As a contrast in 32Dp210 cells, however, there was a significant decrease in Cdc42-GTP level and Rac1-GTP level remained unchanged in response to SDF-1a. It should be noted that basal levels of active Cdc42 and Rac1 were higher in 32Dp210 than in 32D cells with equivalent level of CXCR4 expression ( Figure 1c) .
Next, we determined whether the tyrosine kinase activity of p210
BcrÀAbl is necessary for the upregulation of Cdc42 and Rac1 in transformed 32Dp210 cells. Cells were treated with Gleevec to inhibit p210
BcrÀAbl kinase (Deininger et al., 2005) before carrying out Cdc42/Rac1 activity assays. Gleevec treatment markedly decreased Cdc42 and Rac1 activities in 32Dp210 cells, but had little effect in parental 32D cells (Figures 2a and b) . This suggests that deregulated kinase activity of p210 BcrÀAbl was responsible for the elevation of Cdc42/Rac1 activity in 32Dp210 cells. Correlated with Cdc42/Rac1 activation in response to SDF-1a, the parental 32D cells showed a very clear response to SDF-1a for directed migration in the transwell assay, and Gleevec exposure did not alter this response (Figure 2c ). In contrast, 32Dp210 cells, as expected, showed little response to SDF-1a in directional migration, whereas Gleevec treatment significantly restored their capacity in SDF1a-directed migration. (Figures 2a and b) . Furthermore, the repression of Cdc42 activity by Gleevec treatment seemed to be time-and dosage-dependent in K562 cells (data not shown), suggesting that p210 BcrÀAbl kinase activity is required for sustained Cdc42 activation. Owing to the lack of CXCR4 expression, K562 cells did not show SDF-1a response (data not shown).
Effect of inhibiting p210
BcrÀAbl PTK on Cdc42 and Rac1 activities, and SDF-1a chemotaxis in Ph( þ ) primary cells from CML patients To extend these findings to a more clinically relevant condition, we isolated primary mononuclear cells from BM cells of two Ph( þ ) CML patients and treated these cells with Gleevec in serum-containing and serumfree medium for Cdc42/Rac activity assays. Cdc42 activity was decreased by more than 30% in both serum-containing and serum-free media by inhibiting p210
BcrÀAbl kinase (Figure 3a) . Meanwhile, endogenous Rac1 activity was also reduced by Gleevec treatment in Ph( þ ) cells (Figure 3b ). We further used Boyden chamber assay to examine the effect of Gleevec treatment on SDF-1a-dependent directional migration in cells isolated from BM of these two Ph( þ ) patients ( Figure 3c ). Consistently, Gleevec treatment was able to increase the migration capacity of the patient CML cells toward SDF-1a. Again, these results showed that the decrease in Cdc42 and Rac1 activities due to the inhibition of tyrosine kinase of p210
BcrÀAbl is closely associated with the increase of SDF-1a-directed migration in CML cells.
Cdc42 GTPase regulates SDF-1a-induced response
We further carried out time-lapse recordings to compare the morphological changes of 32D and 32Dp210 cells in SDF-1a-induced chemotaxis. SDF-1a induced dynamic finger-like outward projections in 32D cells ( Figure 4a ) and Gleevec treatment had no effect on the changes (Figure 4b and Supplementary movie 1). In contrast, 32Dp210 cells showed little response to SDF-1a stimulation ( Figure 4b and Supplementary movie 2). In agreement with data from the transwell assay, Gleevec treatment conferred 32Dp210 cells the dynamic SDF-1a response as seen in 32D cells. Given that Cdc42 regulates cell polarity and Rac works in membrane protrusion of migrating cells by promoting actin polymerization for directional migration, we tranfected 32D cells with GFP-tagged Cdc42N17, Cdc42V12, Rac1N17 or Rac1V12, corresponding to dominant negative and constitutively active forms of Cdc42 and Rac1, respectively, to test their role in SDF-1a-stimulated finger-like protrusions ( Figure 4c and Supplementary movie 3). We found that overexpression of Cdc42V12 or Cdc42N17, but not Rac1V12 or Rac1N17, was able to diminish SDF-1a-induced finger-like protrusions. Clearly, SDF-1a-induced finger-like protrusions require a tight regulation of Cdc42. We further tested whether Gleevec treatment is able to restore Cdc42 activation by SDF-1a in 32Dp210 cells. The results showed that Cdc42 activity was stimulated by SDF-1a in Gleevec-treated 32Dp210 cells (Figure 4d ), which is consistent with the restored finger-like projection ( Figure 4b ) and migratory response ( Figure 2c ).
Enforced activation of Cdc42 perturbs restored SDF-1a chemotaxis of Gleevec-treated CML cells
The aforementioned results showed that elevated steadystate level of Cdc42 activity in CML cells was inversely correlated with their capacity in SDF-1a-induced directional migration and that deregulation of Cdc42 blocked SDF-1a response. Accordingly, we hypothesized that too much Cdc42 activation in Ph( þ ) cells would contribute to the defect in the SDF-1a-mediated chemotaxis. To validate this hypothesis, we then Figure 1 Stromal-derived factor-1a (SDF-1a) differentially activates Cdc42 and Rac1 GTPases in 32D and 32Dp210 cells. (a and b) 32D and 32Dp210 cells deprived of serum for 18 h were treated with or without murine SDF-1a (500 ng/ml) for 5 min for measuring the amounts of Cdc42-GTP (a) and Rac1-GTP (b) by GST-PBD (glutathione S-transferase-Rac/Cdc42 binding domain of p21 activated kinase 1 protein) pull-down assays. The western blot analysis was performed using Cdc42 and Rac1 antibodies. The top panel shows the western blot analysis for Cdc42 (a) and Rac1 (b) in the GTP-bound form that associates with GST-PBD and 8% of total input. By densitometric scanning, active Rho GTPase was measured and its percentage relative to total Rho GTPase was calculated. Average values from three individual experiments are shown below the western blot data. The intensity ratio of Rho GTPase in GTP-bound form to total Rho GTPase in lysate of 32D cells without SDF-1a treatment was set to 1, and the relative fold of active Rho GTPase for each condition is shown in the lower panel as means±s.d. (n ¼ 3) ('*' indicates Po0.05; '**' indicates Po0.01). (c) The expression of chemokine (CXC motif) receptor 4 (CXCR4) in 32D and 32Dp210 cells was detected by western blot using anti-CXCR4 antibody. Actin is shown as a loading control.
transduced the constitutively active form of TatCdc42V12 into freshly isolated mononuclear cells from leukemia patient that were verified to be Ph chromosome negative (Ph(À)) for the transwell assays. As expected, Ph(À) leukemia cells were capable of SDF-1a-directed migration and Gleevec treatment had no effect on their SDF-1a responsiveness (Figure 5a ). Addition of Tat-Cdc42V12 increased random migration, and abrogated SDF-1a-directed responsiveness. As for mononuclear cells isolated from BM of four different Ph( þ ) CML patients, these CML cells consistently showed a defect in SDF-1a-stimulated directional migration and Gleevec treatment restored their SDF-1a responsiveness (Figure 5b ). Similar to Ph(À) cells, addition of TatCdc42V12 increased random motility of primary Ph( þ ) cells in all cases and abolished SDF-1a-responsiveness in Gleevec-treated Ph( þ ) CML cells, supporting our idea that sustained activation of Cdc42 is able to impair SDF-1a-responsive directional migration.
Vav1 mediates p210
BcrÀAbl -induced Cdc42 activation It has been reported that Vav1 serves as a direct PTK substrate of p210
BcrÀAbl (Matsuguchi et al., 1995) and forms a complex with the Abl portion of p210
BcrÀAbl for Rac1 stimulation (Bassermann et al., 2002; Daubon et al., 2008) . In addition, phosphorylation and activation of Vav1, induced by SDF-1a, controls the chemotactic response in human primary lymphocytes (Vicente-Manzanares et al., 2005) . To verify the relationship between deregulated kinase activity of p210
BcrÀAbl and Vav1 activation for Cdc42/Rac1 upregulation, we first analyzed the phosphorylation status of immunoprecipitated Vav1 in 32D, 32Dp210 and K562 cells in response to Gleevec treatment. In agreement, the extent of Vav1 phosphorylation was clearly higher in 32Dp210 and K562 cells, and Gleevec treatment abolished the p210 BcrÀAbl -promoted phosphorylation signal of Vav1 (Figure 6a ). We then transfected 32D cells with an expression vector of Vav1 deletion mutant (D1-186), which is a constitutively active Vav1, independent of phosphorylation control (Lopez-Lago et al., Figure 2 Inhibition of p210
BcrÀAbl tyrosine kinase inactivates Cdc42 and Rac1 GTPases and restores SDF-1a chemotaxis. (a and b) Murine 32D and 32Dp210 cells were maintained in serum-free medium for 12 h and then treated with or without Gleevec (2 mM) for additional 6 h. Human K562 cells were incubated in serum-free medium in the presence or absence of Gleevec (5 mM) for 18 h. Cells were then collected for GST-PBD pull-down assays. The representative amounts of active and total Cdc42 (a) and Rac1 (b) are shown in the top panel. The intensity ratio of Rho GTPase in GTP-bound form to total Rho GTPase in lysate of 32D/K562 cells without Gleevec treatment was set to 1, and the relative fold of active Rho GTPase for each condition is shown in the lower panel as means±s.d. (n ¼ 3) ('*' indicates Po0.05; '**' indicates Po0.01). (c) 32D and 32Dp210 cells treated as described above were then re-suspended in fresh medium and seeded in triplicate into the upper chamber of the transwell. The lower chamber of the transwell was filled with serum-free medium with or without murine SDF-1a (100 ng/ml). After 4 h, transmigrated cells recovered from the lower chamber were counted. The percentage of migration was calculated by dividing the transmigrated number by the total cells in the initial suspension (10 5 ). Data are represented as mean ± s.d. of six transwell experiments from two independent treatments (n ¼ 6) ('*' indicates Po0.05; '**' indicates Po0.01).
2000)
. The results showed that overexpression of Vav1(D1-186) was sufficient to activate Cdc42 in 32D cells (Figure 6b ). Conversely, Cdc42 activity was decreased in 32Dp210 cells when Vav1 expression level was decreased by Vav1-specific shRNA transfection (Figure 6c ), indicating the essential role of Vav1 in the activation of Cdc42 in these transformed cells.
Discussion
Rho family GTPases, RhoA, Rac1 and Cdc42, have a pivotal role in cytoskeleton rearrangement during directional migration. However, whether or not p210
BcrÀAbl transformation disturbs SDF-1a response through these Rho GTPases remains undefined. In this BcrÀAbl tyrosine kinase decreases Cdc42/Rac1 activities and restores chemotaxis in primary Ph( þ ) cells. (a and b) Primary mononuclear cells isolated from BM samples were maintained in serum-containing or serum-free RPMI 1640 medium treated with or without Gleevec (5 mM) for 18 h. Representative CML cells from Ph( þ )1 and Ph( þ )2 patients were collected and lysed for Cdc42/Rac1 activity assays. The top panel shows the GTP-bound Cdc42 (a) and Rac1 (b), and the total amount of GTPases in 10% of total cell extract from Ph( þ )1 patient. The intensity ratio of Rho GTPase in GTP-bound form to total Rho GTPase in the lysate of primary cells in serum-containing medium without treatment was set to 1, and the relative fold of active Rho GTPase for each condition is shown from Ph( þ )1 (n ¼ 1) and Ph( þ )2 (n ¼ 2) patients in the lower panel. (c) CML cells from Ph( þ )1 and Ph( þ )2 patients treated in serum-free medium as described above were re-suspended in fresh serum-free medium and then added to the upper chamber of the transwell in triplicate. The lower chamber of the transwell was filled with serum-free medium with or without human SDF-1a (200 ng/ml). After 4 h of incubation, transmigrated cells recovered from the lower chamber were counted as described in Materials and methods section. Data are represented as mean ± s.d. of six transwell assays from two independent treatment experiments ('**' indicates Po0.01).
study, we provide new insights into the interplay between p210
BcrÀAbl and Cdc42 in the regulation of the chemotactic migration of CML progenitors. Although Cdc42 activation is required for cell motility, here our results suggest that sustained activation of Cdc42 by p210
BcrÀAbl signaling in CML cells disrupts SDF-1a-induced polarization signal, offering a possible explanation for premature circulation of undifferentiated myeloid cells without BM retention in CML disease.
The chemoattractant, SDF-1a, and its receptor, CXCR4, are essential for myeloid and lymphoid development. Defects in SDF-1a responsiveness in p210
BcrÀAbl -transformed cells, therefore, have certain functions in the pathogenesis of CML. Theoretically, hematopoietic cells in BM might sense the SDF-1a signal to initiate receptor-mediated Cdc42 and Rac1 activation, resulting in cytoskeletal polarization as manifested by the increase in filopodia-and lamellipodia-like structures to orientate cell movement and homing. One possible mechanism contributory to the deficiency of SDF-1a responsiveness in p210
BcrÀAbl -transformed and CML cells could be the loss of CXCR4 function or expression in these cells. It has been shown that p210
BcrÀAbl utilizes its tyrosine kinase activity to inhibit SDF-1a chemotactic response through downregulation of CXCR4 mRNA expression in blasticphase CML cells and MO7e cells expressing high level of p210
BcrÀAbl (Geay et al., 2005) . However, our data BcrÀAbl -mediated deregulation of Cdc42. (a and b) 32D and 32Dp210 cells deprived of serum for 18 h were re-suspended in serum-free medium and plated onto fibronectin-coated glass slide assembled in the POC-R open cultivation chamber. Cells were then treated with murine SDF-1a (25 ng/ml) for time-lapse recording at 15-s intervals and were imaged using Â 100 DIC objective for 20 min. The morphology of representative 32D cells treated with or without SDF-1a was shown as indicated in (a). The total numbers of finger-like projection from 80 frames were counted by MetaMorph software and the projection numbers are shown as the mean ± s.d. of five cells from at least three independent treatments ('**' indicates Po0.01) (b). (c) 32D cells were transfected with green fluorescent protein (GFP) or GFP-tagged dominant active or negative Cdc42 and Rac1 plasmids. Transfected cells were re-suspended in serum-free medium for 18 h and SDF-1a-induced finger-like projections were observed and quantified as described above (n ¼ 5). (d) 32Dp210 cells deprived of serum for 15 h were then treated with or without Gleevec (2 mM) for 3 h. Cells were then stimulated with or without murine SDF-1a (500 ng/ml) for 5 min for measuring the amounts of Cdc42-GTP by GST-PBD pull-down assays and the western blot using Cdc42 antibody. The representative western blot in top panel shows the Cdc42 in the GTP-bound form that associates with GST-PBD and 7% of total input. By densitometric scanning, the intensity ratio of Cdc42 in GTP-bound form to total Cdc42 in lysate of 32Dp210 cells with Gleevec treatment was set to 1, and the relative fold of active Cdc42 for each condition is shown in the lower panel as means ± s.d. of three individual experiments ('*' indicates Po0.05).
indicate that neither p210
BcrÀAbl transformation in the 32D progenitor model nor p210
BcrÀAbl inhibition by Gleevec in CML cells from chronic-phase patients had any effect on the modulation of CXCR4 protein expression. Moreover, p210
BcrÀAbl inhibition was able to restore SDF-1a response, suggesting the intact function of CXCR4 in p210 BcrÀAbl transformation. Another possibility is related to the defective signaling in either SDF-1a-induced Cdc42 or Rac activation in CML cells. As a matter of fact, Cdc42 and Rac1 were constitutively activated in CML cells. Inhibition of p210
BcrÀAbl by Gleevec markedly decreased Cdc42 activity with a concurrent increase of SDF-1a-stimulated directional migration. Unlike 32D progenitor cells in which Cdc42 and Rac1 activities were increased by SDF-1a stimulation, p210
BcrÀAbl -transformed 32Dp210 cells showed no change in Rac1 activity, but an unexpected decline in Cdc42 activity. At present, we do not know why Cdc42 activity was specifically decreased in 32Dp210 cells after SDF-1a treatment. Nevertheless, our results, at least, indicated the SDF-1a-induced activation of Cdc42 and Rac1 is defective after p210
BcrÀAbl transformation. RhoA, Rac1 and Cdc42 GTPases have been shown to be activated by p210
BcrÀAbl transformation through its Dbl-homology domain of Bcr and its target Vav1 for the and Ph( þ ) (b) BM were treated with or without Gleevec in serum-free RPMI 1640 medium for 18 h. Cells were then re-suspended in fresh serum-free medium with or without Tat-Cdc42V12 (20 mg/ml) for 10 min and then seeded in the transwells in triplicate. The lower chamber of the transwell was filled with serum-free medium with or without human SDF-1a (200 ng/ml). After 4 h of incubation, transmigrated cells recovered from the lower chamber were counted as described in Materials and methods. Data are represented as mean ± s.d. of six transwell assays from two independent treatment experiments (n ¼ 6) ('*' indicates Po0.05; '**' indicates Po0.01).
Figure 6 The involvement of Vav1 in p210
BcrÀAbl -mediated Cdc42/Rac1 GTPase activation. (a) 32D, 32Dp210 and K562 cells treated with or without Gleevec as described in Figure 2 were lysed and subjected to immunoprecipitation for Vav1. Immunoprecipitates were separated by SDS-PAGE, immunoblotted with antibody against P-Tyr (PY), and then re-probed with Vav1 antibody. (b) 32D cells transfected with GFP or GFP-Vav1(D1-186) were maintained in culture medium for 8 h. Transfection efficiency was higher than 60% in all experiments examined by Olympus AX-70 fluorescence microscopy by detecting GFP-positive population. Cells were then subjected to GST-PBD pull-down assays. Rho GTPases in GTP-bound form and in total lysates were analyzed by western blot with anti-Cdc42 antibody and re-probing with anti-Rac1 antibody. By densitometric scanning, the relative fold of active to total Rho GTPase in each lysates was determined from three independent experiments (mean±s.d.) shown in the left panel. Expression levels of GFP and GFP-Vav1(D1-186) were confirmed by western blot using anti-GFP and anti-Vav1 antibodies in the right panel. Actin is shown as a loading control. The molecular weight of GFP-Vav1(D1-186) is the same as endogenous Vav1, and is also detected by Vav1 antibody (c) 32Dp210 cells transfected with control LacZ or Vav1-specific shRNA plasmid were maintained in serum-containing culture medium for 48 h. Cells were then subjected to GST-PBD pull-down assays for the detection of Cdc42 and Rac1 activities. The left panel shows the representative blot and quantification data of Cdc42 and Rac1 activities from six independent assays. The right panel shows representative Vav1 knockdown efficiency in total lysates using anti-Vav1 antibody. Actin is shown as a loading control. (d) Proposed model of p210
BcrÀAbl in chemotaxis. p210
BcrÀAbl deregulates Cdc42 GTPase through phosphorylation and activation of Vav1, which abrogates SDF-1a-induced Cdc42 activation, thus blocking chemotaxis in chronic myeloid leukemia (CML). guanine nucleotide exchange factor (GEF) activity in hematopoietic BaF3 cells (Harnois et al., 2003; Daubon et al., 2008) . However, RhoA activity was almost undetectable in BM-derived Ph( þ ) primary cells (data not shown). Although p210
BcrÀAbl phosphorylates Vav1 to activate Rac1 in 293 cells (Bassermann et al., 2002) , we found less alteration of Rac1 as compared with Cdc42 activity in K562 cells after Gleevec treatment. As for 32Dp210-transformed cells, inhibition of p210
BcrÀAbl also abolished Vav1 phosphorylation but with both Cdc42 and Rac1 activities being suppressed. Thus, the correlation between p210
BcrÀAbl -dependent phosphorylation of Vav1, and Cdc42 and Rac1 activation varies in different cell types. As decreasing the expression of Vav1 by shRNA transfection downregulated Cdc42/Rac1 activities, activation of Vav1 by p210
BcrÀAbl signaling contributed to the elevation of Cdc42/Rac1 activities in 32Dp210-transformed cells. Consistent with what was observed in 32Dp210 cells, Gleevec treatment in CML cells from Ph( þ ) chronic phase patients decreased Cdc42 and Rac1 activities and restored SDF-1a-directed migration, confirming the contribution of p210
BcrÀAbl PTK activity to deregulation of these actin polymerization signals.
Noticeably, the SDF-1a-induced finger-like protrusions were more sensitive to deregulation of Cdc42 instead of Rac1. Interestingly, both p210
BcrÀAbl transformation and SDF-1a stimulation resulted in about a twofold increase in Cdc42 GTPase in 32D cells.
Conversely, inhibition of p210
BcrÀAbl in 32Dp210 cells resulted in about twofold decrease in Cdc42 activity and restored Cdc42 activation in response to SDF-1a. Likely, a tight control of Cdc42 activation magnitude is crucial for the cytoskeletal changes in chemotaxis and is interfered by kinase function of p210
BcrÀAbl . In support of this view, transduction of Tat-Cdc42V12 in CML cells from patients was sufficient to abrogate the Gleevec effect on restoring SDF-1a-directed migration. Particularly, it is noted that random migration of all myeloid cells was increased by Tat-Cdc42V12, suggesting that deregulated Cdc42 activation promotes random motility and impairs chemotaxis.
Considering the essential role of Cdc42 regulation in actin polymerization and cell polarity, here we proposed that oncogenic p210
BcrÀAbl transformation deregulates Cdc42 activation to desensitize SDF-1a-induced polarized signal required for directional migration, thereby contributing to the homing and retention defects seen in CML (Figure 6d ).
Materials and methods
Chemicals and Tat-Cdc42V12 protein Bcr-Abl tyrosine kinase inhibitor Gleevec (also named as STI571, imatinib mesylate and Glivec) (Novartis AG, Basel, Switzerland) was dissolved in ddH 2 O. Recombinant chemokine human or murine SDF-1a (Cytolab/PeproTech, Rocky Hill, NJ, USA) were dissolved in phosphate buffered saline containing 0.1% bovine serum albumin. Recombinant Tat-Cdc42V12 protein was produced in Escherichia coli and purified by sequential Ni-NTA agarose pull-down assay, Imidazole elution and phosphate buffered saline dialysis as previously described (Chang et al., 2006) .
Cell lines and primary cells
Human erythroleukemia cell line K562 was maintained in RPMI 1640 (Gibco-BRL, Eggenstein, Germany) supplemented with 10% heat-inactivated fetal bovine serum (Hyclone, Logan, UT, USA), 2 mM L-glutamine, 100 U/ml penicillin and 100 U/ml streptomycin. The murine WEHI and p210 BcrÀAbl -transformed 32Dp210 cells were kindly provided by Dr RB Arlinghaus (The University of Texas MD Anderson Cancer Center, Houston, TX, USA.) and cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin and 100 U/ml streptomycin, 1.5 g/l sodium bicarbonate, 10 mM HEPES and 1 mM sodium pyruvate. Mouse 32D (32Dcl3) cells were purchased from American Type Culture Collection and maintained in the same medium used for transformed 32Dp210 cell line with 25% WEHI-cultured conditioned medium as a source of interleukin-3.
Fresh primary leukemia samples without any advanced chemotherapy were collected from BM of Ph( þ ) (n ¼ 4) and Ph(À) (n ¼ 1) patients during medical evaluations. Informed consent was approved by the Institutional Review Board. Mononuclear cells were isolated using Ficoll-Paque PRE-MIUM (Amersham Biosciences, Uppsala, Sweden) density gradient separation and were maintained in the same RPMI 1640 medium used for K562 cells.
Endogenous Rho GTPase activity assay Activation of Rho GTPases is manifested by their capacity in binding the interacting domain present in their corresponding effector protein. In this study, the GST-PBD (GST, glutathione S-transferase; PBD, Rac/Cdc42 binding domain of p21 activated kinase 1 protein) pull-down assays were used to detect cellular GTP-bound Rac1 and Cdc42, respectively (Stofega et al., 2006) . In brief, cells were lysed in a buffer containing 50 mM Tris-HCl (pH 7.2), 1% (v/v) Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 500 mM NaCl, 10 mM MgCl 2 , 1 mM phenylmethanesulphonyl fluoride (PMSF) and 100 Â dilution of protease inhibitor cocktail (Sigma, St Louis, MO, USA). The supernatants of the lysates were incubated at 4 1C for 1.5 h with GST-PBD-coupled glutathione-sepharose beads. The beads were washed three times with buffer containing 50 mM Tris-HCl (pH 7.2), 1% (v/v) Triton X-100, 150 mM NaCl, 10 mM MgCl 2 , 0.1 mM PMSF and 1000 Â dilution of protease inhibitor cocktail. The amounts of total and GTP-bound Rho GTPases were detected by western blotting with an antibody against Rac1 (Millipore/Upstate, Billerica, MA, USA) or Cdc42 (Millipore/Upstate or Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Transwell chemotaxis assay
The assays were carried out by using 8-mm pore filter (Transwell, 24-well plate; Corning Costar, Lowell, MA, USA) for indicated conditions. Murine 32D and 32Dp210 cells were maintained in migration medium (serum-free RPMI 1640 medium) for 12 h and then treated with or without Gleevec (2 mM) for additional 6 h. Primary human BM cells were pre-incubated in migration medium with or without Gleevec (5 mM) for 18 h. Cells (10 5 ) were then re-suspended in migration medium and placed in the upper chamber of the transwell in triplicate. The lower chamber of the transwell was filled with 600 ml migration medium with or without murine SDF-1a (100 ng/ml), or with or without human SDF-1a (200 ng/ml). After 4 h of incubation, the upper chamber was carefully removed, and cells that had migrated to the bottom chamber were re-suspended and manually counted using a hemocytometer. The percentage of migrated cells was calculated as: (number of migrated cells/10 5 ) Â 100% and the results were obtained from two independent treatment assays and shown as mean ± s.d. (n ¼ 6).
Transient electroporation transfection DNA transfection in 32D or 32Dp210 cells was carried out using MicroPorator MP-100 (Digital Bio Technology, Seoul, Korea). A total of 5 Â 10 6 cells were suspended in 100 ml Resuspension buffer with 10 mg transfection DNA and transferred to a Gold-Tip, followed by electroporation in electrolytic buffer at 1350 V per 30 ms. Cells were then maintained in cultured medium without antibiotics for at least 8 h.
Differential interference contrast (DIC) microscopy for live-cell imaging Live-cell imaging was carried out using MetaMorph 7.1 software to control a digital imaging system coupled to an inverted microscope (Axiovert 200M; Zeiss, Jena, Germany). A high-sensitivity CoolSNAP HQ CCD camera acquired images using the MetaMorph software. Live-cell imaging for cells cultured on the POC-R2 open cultivation chamber (PeCon, Erbach, Germany) was carried out by 100 Â DIC PlanApo oil objective (NA 1.3). Time lapse DIC video recordings were acquired every 15 s for 20 min (80 continuous frames in total) on murine SDF-1a (25 ng/ml) stimulation.
Vav1 immunoprecipitation
Cells were collected in ice-cold lysis buffer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM MgCl 2 , 1% Triton X-100, 1 mM EGTA, 1 mM EDTA, 40 mM NaF, 2 mM Na 3 VO 4 , 1 mM PMSF and 100 Â dilution of protease inhibitor cocktail) (Wilkinson et al., 2006) . Supernatants from lysates (1 mg of total protein) were incubated with the anti-Vav1 antibody or normal rabbit IgG for 2 h at 4 1C and protein A-agarose were added for additional 0.5 h. Immune complexes were washed three times in lysis buffer. The immunoprecipitates were subjected to SDS-PAGE immunoblot analysis using the anti-Vav1 (Santa Cruz Biotechnology) and anti-P-Tyr (clone 4G10, Millipore/ Upstate) antibodies.
